Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression

NCT04022876 is registered in ClinicalTrials.gov with Aileron Therapeutics, Inc. as lead sponsor.

NCT NCT04022876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04022876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
Lead sponsor
Aileron Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 3, 2019
Completion date
August 30, 2022
Enrollment
35 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, small-cell lung cancer